查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615477

HIV 疫苗市場：按階段、類別、抗體、最終用戶 - 2025-2030 年全球預測

HIV Vaccines Market by Phase (Phase I, Phase II, Phase III), Category (Preventive Vaccines, Therapeutic Vaccines), Antibodies, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年HIV疫苗市場價值為83508萬美元，預計2024年將達到94005萬美元，複合年成長率為12.88%，到2030年將達到195126萬美元。

HIV疫苗市場的範圍和定義包括旨在預防人類免疫力缺乏病毒（HIV）感染的疫苗的開發、生產和分銷。 HIV/愛滋病對全球數百萬人的持續影響以及目前缺乏抗逆轉錄病毒治療和暴露前預防 (PrEP) 等預防措施的有效性有限，推動了對 HIV 疫苗的需求。主要用途是高危險群，例如醫護人員、有高危險性行為的個人、愛滋病毒流行率高的地區。最終使用領域包括希望將這些疫苗納入更廣泛的公共衛生策略的醫院、研究機構和社區健康中心。推動市場成長的主要因素包括研發方面的大量投資、意識的提高、政府激勵以及生物技術的進步，這些因素導致生物技術公司利用公共衛生服務來推進臨床試驗。潛在的商機在於老牌製藥公司和創新生物技術公司之間擴大合作，利用基因工程和合成生物學來創造更有效的候選疫苗。抓住這些機會的建議包括加強策略聯盟和增加突破性臨床試驗的資助。然而，市場成長受到不斷上升的研發成本、複雜的監管核准流程、臨床實驗人群的道德考慮以及疫苗分配和管理的困難（尤其是在資源有限的環境下）的阻礙。為了克服這些挑戰，公司必須專注於創新領域，例如 mRNA 疫苗技術（該技術已在其他病毒感染疾病中顯示功效）以及針對不同人群遺傳標記的個人化疫苗。市場考慮表明，創新的緊迫性加劇了競爭，但透過共用的全球健康目標培育的協作生態系統平衡了競爭。優先考慮永續實踐和公平獲取不僅能帶來業務成長，還能對全球健康產生變革性影響。

主要市場統計
基準年[2023] 83508萬美元
預計年份 [2024] 94005萬美元
預測年份 [2030] 1,951.26 百萬美元
複合年成長率（%） 12.88%

市場動態：揭示快速發展的愛滋病疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變愛滋病毒疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全世界對愛滋病的認知不斷提高以及對有效治療的需求
    • 政府對愛滋病治療藥物的支持體系與政策
    • 政府和非政府組織加強針對愛滋病毒流行的宣傳活動
  • 市場限制因素
    • 與愛滋病毒疫苗商業化和標準化相關的嚴格法規
  • 市場機會
    • 利用 CRISPR 基因編輯和人工智慧進行 HIV 預測模型的創新
    • 政府機構和生技公司之間的研發夥伴關係關係增加
  • 市場挑戰
    • 與配方和產品召回案例相關的複雜性

波特五力：引領愛滋病疫苗市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 HIV 疫苗市場的外部影響

外部宏觀環境因素在塑造愛滋病疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解愛滋病疫苗市場的競爭格局

HIV 疫苗市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 HIV 疫苗市場供應商績效評估

FPNV定位矩陣是評估HIV疫苗市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製愛滋病疫苗市場的成功之路

HIV 疫苗市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地對愛滋病的認知不斷提高，對有效治療的需求也隨之增加。
      • 政府對愛滋病毒藥物的支持框架與政策
      • 政府和非政府組織加強宣傳活動，提高人們對愛滋病毒流行的認知
    • 抑制因素
      • 與愛滋病毒疫苗商業化和標準化相關的嚴格法規
    • 機會
      • CRISPR 基因編輯和人工智慧驅動的 HIV 預測模型的創新
      • 政府機構和生技公司之間的研發夥伴關係關係增加
    • 任務
      • 藥品處方和產品召回案例的複雜性
  • 市場區隔分析
    • 階段：分幾個階段對愛滋病毒疫苗進行嚴格測試，以確保公眾健康
    • 最終用戶：在公共保健機構中廣泛使用愛滋病毒疫苗以控制和消除愛滋病毒流行
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 HIV 疫苗市場分階段

  • 第一階段
  • 第二階段
  • 第三階段

第7章 HIV 疫苗市場：依類別

  • 預防性疫苗
  • 治療性疫苗

第8章 HIV 疫苗市場（按抗體）

  • 10E8
  • 廣泛中和抗體
  • PG9 和 PG16
  • ＶＲＣ０１

第9章 HIV 疫苗市場：依最終用戶分類

  • 臨床研究中心
  • 醫院
  • 公立醫療機構

第10章美洲HIV疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太HIV疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲HIV疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Uvax Bio 在澳洲透過臨床試驗推進 HIV 疫苗的開發
    • FDA核准新型 HIV 疫苗 HB-500 的人體試驗
    • Absai 與加州理工學院之間的創新合作開發出負擔得起的愛滋病毒治療疫苗
  • 戰略分析和建議

公司名單

  • AlphaVax, Inc.
  • Antigen Express, Inc. by Generex Biotechnology Corporation
  • Argos Therapeutics, Inc.
  • Bavarian Nordic
  • Bionor Holding AS
  • Celldex Therapeutics, Inc.
  • GeneCure LLC
  • Genetic Immunity, Inc.
  • GenVec, Inc.
  • GeoVax Labs, Inc.
  • GlaxoSmithKline PLC
  • Immune Response BioPharma, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Moderna Inc.
  • Novartis AG
  • Oncolys BioPharma Inc.
  • Sanofi SA
  • TVAX Biomedical, Inc.
Product Code: MRR-4312A385A507

The HIV Vaccines Market was valued at USD 835.08 million in 2023, expected to reach USD 940.05 million in 2024, and is projected to grow at a CAGR of 12.88%, to USD 1,951.26 million by 2030.

The scope and definition of the HIV vaccines market encompass the development, production, and distribution of vaccines aimed at preventing Human Immunodeficiency Virus (HIV) infections. The necessity for HIV vaccines arises from the continuous global impact of HIV/AIDS, with millions affected worldwide, and the limited effectiveness of current preventive measures like antiretroviral therapies and pre-exposure prophylaxis (PrEP). The primary applications involve their use in at-risk populations, including healthcare workers, individuals with high-risk sexual behavior, and regions with high HIV prevalence. End-use scopes include hospitals, research institutes, and community health centers aiming to integrate these vaccines into broader public health strategies. Key factors driving market growth include substantial investments in R&D, rising awareness, and government incentivization, alongside advancements in biotechnology, which foster biotechnology companies to partner with public health organizations to advance clinical trials. Potential opportunities lie in the growing collaborations between established pharmaceutical firms and innovative biotechs, leveraging genetic engineering and synthetic biology to create more effective vaccine candidates. Recommendations to seize these opportunities include enhancing strategic alliances and increasing funding towards groundbreaking clinical trials. However, market growth is hampered by high R&D costs, complex regulatory approval processes, and ethical considerations in trial populations, as well as logistical challenges in ensuring vaccine distribution and administration, especially in resource-limited settings. To overcome these, businesses must focus on areas of innovation such as mRNA vaccine technologies, which have shown efficacy in other viral infections, and personalized vaccines tailored to genetic markers of diverse populations. Insights into the market suggest a competitive nature intensified by the urgency to innovate, yet balanced by the collaborative ecosystem fostered by shared global health objectives. Prioritizing sustainable practices and equitable access promises not only business growth but also transformative health impacts on a global scale.

KEY MARKET STATISTICS
Base Year [2023] USD 835.08 million
Estimated Year [2024] USD 940.05 million
Forecast Year [2030] USD 1,951.26 million
CAGR (%) 12.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HIV Vaccines Market

The HIV Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing awareness about AIDS worldwide and the need for effective medications
    • Supportive government frameworks and policies for HIV drugs
    • Increasing number of government and NGO campaigns for awareness of the HIV epidemic
  • Market Restraints
    • Strict regulations associated with the commercialization and standardization of HIV vaccines
  • Market Opportunities
    • Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
    • Increasing number of R&D partnerships between government bodies and biotechnology firms
  • Market Challenges
    • Complexities associated with drug formulation and cases of product recalls

Porter's Five Forces: A Strategic Tool for Navigating the HIV Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HIV Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HIV Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HIV Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HIV Vaccines Market

A detailed market share analysis in the HIV Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HIV Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HIV Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HIV Vaccines Market

A strategic analysis of the HIV Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HIV Vaccines Market, highlighting leading vendors and their innovative profiles. These include AlphaVax, Inc., Antigen Express, Inc. by Generex Biotechnology Corporation, Argos Therapeutics, Inc., Bavarian Nordic, Bionor Holding AS, Celldex Therapeutics, Inc., GeneCure LLC, Genetic Immunity, Inc., GenVec, Inc., GeoVax Labs, Inc., GlaxoSmithKline PLC, Immune Response BioPharma, Inc., Inovio Pharmaceuticals, Inc., Johnson & Johnson, Moderna Inc., Novartis AG, Oncolys BioPharma Inc., Sanofi S.A., and TVAX Biomedical, Inc..

Market Segmentation & Coverage

This research report categorizes the HIV Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, and Phase III.
  • Based on Category, market is studied across Preventive Vaccines and Therapeutic Vaccines.
  • Based on Antibodies, market is studied across 10E8, Broadly Neutralizing Antibodies, PG9 and PG16, and VRC01.
  • Based on End Users, market is studied across Clinical Research Centers, Hospitals, and Public Healthcare Providers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness about AIDS worldwide and the need for effective medications
      • 5.1.1.2. Supportive government frameworks and policies for HIV drugs
      • 5.1.1.3. Increasing number of government and NGO campaigns for awareness of the HIV epidemic
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulations associated with the commercialization and standardization of HIV vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological innovations in CRISPR gene-editing and AI-driven predictive modeling for HIV
      • 5.1.3.2. Increasing number of R&D partnerships between government bodies and biotechnology firms
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with drug formulation and cases of product recalls
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Rigorous testing of HIV vaccines through several phases to ensure public health
    • 5.2.2. End Users: Extensive usage of HIV vaccines in public healthcare facilities to control and combat the HIV epidemic
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HIV Vaccines Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III

7. HIV Vaccines Market, by Category

  • 7.1. Introduction
  • 7.2. Preventive Vaccines
  • 7.3. Therapeutic Vaccines

8. HIV Vaccines Market, by Antibodies

  • 8.1. Introduction
  • 8.2. 10E8
  • 8.3. Broadly Neutralizing Antibodies
  • 8.4. PG9 and PG16
  • 8.5. VRC01

9. HIV Vaccines Market, by End Users

  • 9.1. Introduction
  • 9.2. Clinical Research Centers
  • 9.3. Hospitals
  • 9.4. Public Healthcare Providers

10. Americas HIV Vaccines Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific HIV Vaccines Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa HIV Vaccines Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Uvax Bio Progresses HIV Vaccine Development with Australian Clinical Trial
    • 13.3.2. FDA Approves Novel HIV Vaccine, HB-500 Vaccine for Human Testing
    • 13.3.3. Innovative Collaboration Between Absci and Caltech to Develop Affordable HIV Therapeutic Vaccine
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AlphaVax, Inc.
  • 2. Antigen Express, Inc. by Generex Biotechnology Corporation
  • 3. Argos Therapeutics, Inc.
  • 4. Bavarian Nordic
  • 5. Bionor Holding AS
  • 6. Celldex Therapeutics, Inc.
  • 7. GeneCure LLC
  • 8. Genetic Immunity, Inc.
  • 9. GenVec, Inc.
  • 10. GeoVax Labs, Inc.
  • 11. GlaxoSmithKline PLC
  • 12. Immune Response BioPharma, Inc.
  • 13. Inovio Pharmaceuticals, Inc.
  • 14. Johnson & Johnson
  • 15. Moderna Inc.
  • 16. Novartis AG
  • 17. Oncolys BioPharma Inc.
  • 18. Sanofi S.A.
  • 19. TVAX Biomedical, Inc.

LIST OF FIGURES

  • FIGURE 1. HIV VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. HIV VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HIV VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY 10E8, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY BROADLY NEUTRALIZING ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY PG9 AND PG16, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY VRC01, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICAL RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HIV VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY ANTIBODIES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HIV VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 191. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2023